Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)

Information

  • Research Project
  • 10212938
  • ApplicationId
    10212938
  • Core Project Number
    R01AI147316
  • Full Project Number
    5R01AI147316-03
  • Serial Number
    147316
  • FOA Number
    RFA-AI-18-037
  • Sub Project Id
  • Project Start Date
    8/1/2019 - 5 years ago
  • Project End Date
    7/31/2024 - 5 months ago
  • Program Officer Name
    SRINIVASAN, SUDHA
  • Budget Start Date
    8/1/2021 - 3 years ago
  • Budget End Date
    7/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    7/29/2021 - 3 years ago

Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)

PROJECT SUMMARY/ABSTRACT Tuberculosis (TB) is the leading infectious disease killer globally and leading cause of death in persons with HIV. The most effective way to reduce TB incidence and mortality is to interrupt transmission. However, this requires finding and treating individuals with TB disease early. The current primary approach to case finding? household contact tracing?identifies <20% of transmissions in high burden settings, leaving a clear and urgent need to identify new groups and settings where TB transmission occurs. Illicit drug use is associated with higher TB infection prevalence and disease incidence, likely due to significant within-group transmission and/or clustered vulnerability. Interrogation of illicit drug use networks for TB transmission, therefore, holds great potential as a target for early case identification and linkage to treatment, with potential benefit for halting transmission to the broader population. Investigators at Boston Medical Center, Stellenbosch University, the South African Medical Research Council, Boston University School of Public Health and the Desmond Tutu HIV Foundation propose to conduct the first study to assess TB risk and disease burden among illicit drug use networks in a high TB/HIV setting and to identify mechanisms for accelerated transmission in this population. We will use respondent driven sampling to recruit 750 individuals, with and without HIV disease, who smoke illicit drugs (methamphetamine and methaqualone) and assess their TB exposure, risk of disease progression, and TB disease burden. Among individuals found to have TB disease, we will leverage whole genome sequencing and social contact interviews to estimate the proportion of cases in this network resultant from recent transmission. We will capture cough frequency and use novel bioaerosol sampling techniques to compare physiologic characteristics of infectiousness between persons who smoke illicit drugs compared to those who do not. Knowledge from this study will provide the basis for a new, focused strategy to interrupt TB transmission in persons who smoke illicit drugs and provide insight into the degree that such transmission fuels overall community spread. These results have potential for generating interventions applicable to many settings where illicit drug use intersects with TB and HIV.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    544860
  • Indirect Cost Amount
    83302
  • Total Cost
    628162
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:628162\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BOSTON MEDICAL CENTER
  • Organization Department
  • Organization DUNS
    005492160
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021182908
  • Organization District
    UNITED STATES